

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

c-Myc (D84C12) XP Rabbit mAb

RRID:AB_1903938

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5605, RRID:AB_1903938

Antibody Information

URL: http://antibodyregistry.org/AB_1903938

Proper Citation: Cell Signaling Technology Cat# 5605, RRID:AB_1903938

Target Antigen: c-Myc (D84C12) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC, F. Consolidation on 10/2018: AB_10484409, AB_10858578, AB_1903938.

Antibody Name: c-Myc (D84C12) XP Rabbit mAb

Description: This monoclonal targets c-Myc (D84C12) XP Rabbit mAb

Target Organism: dg, rat, porcine, h, canine, m, mouse, r, pg, human, mk

Antibody ID: AB_1903938

Vendor: Cell Signaling Technology

Catalog Number: 5605

Record Creation Time: 20250820T030320+0000

Record Last Update: 20250820T151331+0000

Ratings and Alerts

- Used for immunocytochemistry by the Human Islet Research Network community.
Contact(s): [Peng Wang](#), [Andrew Stewart](#) - Human Islets Research Network

No alerts have been found for c-Myc (D84C12) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 187 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. Cancer cell, 44(6), 1218.

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. Molecular cell.

Ferrick KR, et al. (2026) Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratio. Communications biology, 9(1).

Fleming AM, et al. (2026) Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor. Cell reports, 45(3), 117063.

Ding J, et al. (2026) CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling. iScience, 29(7), 116409.

Matsuura K, et al. (2026) Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. Cell reports, 45(7), 117630.

Kral AJ, et al. (2026) Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. Molecular cell, 86(1), 60.

Brunner HL, et al. (2026) A multivalent adaptor mechanism drives the nuclear import of proteasomes. Nature communications, 17(1).

Lesire L, et al. (2026) Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. British journal of pharmacology, 183(12), 3355.

Priebe V, et al. (2026) TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia. Science advances, 12(19), eadu3728.

Sunami T, et al. (2026) IGF2BP3 is essential for the growth heterogeneity of colorectal adenoma cells by regulating MYC. iScience, 29(7), 116535.

Bernardi F, et al. (2026) Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma. *Cancer cell*.

Calderon-Aparicio A, et al. (2026) S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer. *International journal of molecular sciences*, 27(4).

Mitra T, et al. (2026) MEK-dependent bioenergetic demand drives terminal CD8⁺ T cell exhaustion. *Immunity*.

Li G, et al. (2025) Microenvironmental γ -TrCP negates amino acid transport to trigger CD8⁺ T cell exhaustion in human non-small cell lung cancer. *Cell reports*, 44(1), 115128.

Zhang D, et al. (2025) CHI-KAT8i5 suppresses ESCC tumor growth by inhibiting KAT8-mediated c-Myc stability. *Cell reports*, 44(1), 115135.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. *Cell reports. Medicine*, 6(8), 102253.

Mitra T, et al. (2025) MEK-dependent bioenergetic demand drives terminal CD8⁺ T cell exhaustion. *bioRxiv : the preprint server for biology*.

Harper NW, et al. (2025) RNA Pol II inhibition activates cell death independently from the loss of transcription. *Cell*.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. *Cancer discovery*, 15(10), 2054.